Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Classement en actions #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Prix de l'action
$193.62
Capitalisation boursière
$150.08B
Changement (1 jour)
2.76%
Changement (1 an)
184.69%
Pays
GB
Échange AstraZeneca PLC (AZN)

Catégorie

Bénéfices pour AstraZeneca PLC (AZN)
Bénéfices en Dec 2025 TTM : $12.40B
Selon les derniers rapports financiers de AstraZeneca PLC, les bénéfices actuels de l'entreprise sont de $12.40B. En 2024, l'entreprise a réalisé un bénéfice de $8.69B, une augmentation par rapport à celui de 2023 qui était de $6.90B. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour AstraZeneca PLC de 2000 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $12.40B 0.00%
2025 $12.40B 42.70%
2024 $8.69B 25.97%
2023 $6.90B 175.85%
2022 $2.50B -1,043.77%
2021 $-265.00M -106.77%
2020 $3.92B 152.97%
2019 $1.55B -22.33%
2018 $1.99B -10.51%
2017 $2.23B -37.30%
2016 $3.55B 15.74%
2015 $3.07B 146.31%
2014 $1.25B -61.86%
2013 $3.27B -57.27%
2012 $7.65B -37.75%
2011 $12.28B 11.90%
2010 $10.98B 1.57%
2009 $10.81B 24.49%
2008 $8.68B 8.74%
2007 $7.98B -6.56%
2006 $8.54B 28.14%
2005 $6.67B 37.63%
2004 $4.84B 18.81%
2003 $4.08B -6.56%
2002 $4.36B 2.47%
2001 $4.26B 10.58%
2000 $3.85B 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
$25.73B 107.47%
US
$32.58B 162.71%
US
$6.60B -46.81%
US
$16.35B 31.85%
CH
$21.07B 69.87%
US